Plain-English translation of NCT06136364 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called SENL101, which uses your own immune cells (called T cells) that are specially engineered in a laboratory to recognize and fight your cancer. Researchers will give you this therapy and carefully monitor how safe it is and whether it helps shrink your cancer. The study will enroll about 9 patients and will gradually increase the dose to find the safest and most effective level.
T-cell blood cancers (T-ALL and T-LBL) that have come back or stopped responding to chemotherapy are very difficult to treat, and patients have few options left. This medication represents a new approach—using your own immune system's cells as living medicine—to target these aggressive cancers.
You likely qualify if…
You likely don't qualify if…
You will undergo testing to confirm your cancer cells qualify and that your overall health is adequate. Then the treatment team will extract your T cells, send them to a laboratory where they are engineered to target your cancer, and infuse the modified cells back into your body. You will be closely monitored during and after the infusion with blood tests, imaging, and clinical assessments to track how your body responds and whether the treatment is working. The study will follow you for several months to evaluate both safety and effectiveness.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Enrollment target
~9 participants
Started
August 2023
Primary completion
August 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Weili Zhao, Dr
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.